Oral administration of famciclovir for treatment of spontaneous ocular, respiratory, or dermatologic disease attributed to feline herpesvirus type 1: 59 cases (2006-2013)

被引:27
作者
Thomasy, Sara M. [1 ]
Shull, Olivia [4 ]
Outerbridge, Catherine A. [2 ]
Lim, Christine C. [4 ,5 ]
Freeman, Kate S. [4 ,6 ]
Strom, Ann R. [1 ,4 ]
Kass, Philip H. [3 ]
Maggs, David J. [1 ]
机构
[1] Univ Calif Davis, Sch Vet Med, Dept Surg & Radiol Sci, Davis, CA 95616 USA
[2] Univ Calif Davis, Sch Vet Med, Dept Med & Epidemiol, Davis, CA 95616 USA
[3] Univ Calif Davis, Sch Vet Med, Dept Populat Hlth & Reprod, Davis, CA 95616 USA
[4] Univ Calif Davis, Sch Vet Med, Teaching Hosp, Dept Vet Med, Davis, CA 95616 USA
[5] Univ Minnesota, Coll Vet Med, Dept Vet Clin Sci, St Paul, MN 55108 USA
[6] Colorado State Univ, Coll Vet Med & Biomed Sci, Dept Clin Sci, Ft Collins, CO 80523 USA
来源
JAVMA-JOURNAL OF THE AMERICAN VETERINARY MEDICAL ASSOCIATION | 2016年 / 249卷 / 05期
基金
美国国家卫生研究院;
关键词
IN-VITRO; CATS; PHARMACOKINETICS; PENCICLOVIR; ACYCLOVIR; SUSCEPTIBILITY; CONJUNCTIVAL; VALACYCLOVIR; INFECTION; DIAGNOSIS;
D O I
10.2460/javma.249.5.526
中图分类号
S85 [动物医学(兽医学)];
学科分类号
0906 ;
摘要
OBJECTIVE To evaluate outcomes for cats treated with orally administered famciclovir 3 times/d for clinical signs attributed to naturally occurring feline herpesvirus type 1 (FHV-1) infection and to assess variables related to owner satisfaction with the treatment. DESIGN Retrospective case series. ANIMALS 59 client-owned cats. PROCEDURES Medical records were reviewed to identify cats treated for presumed FHV-1 infection from 2006 through 2013 with >= 1 follow-up visit. Signalment, duration of clinical signs, prior treatment, examination findings, diagnostic test results, concurrent treatments, and outcome data were recorded. Owners were asked to complete a survey regarding patient-and treatment-related variables. Data were compared between cats that received low (approx 40 mg/kg [18 mg/lb]) and high (approx 90 mg/kg [41 mg/lb]) doses of famciclovir, PO, 3 times/d. RESULTS Patient age ranged from 0.03 to 16 years. Conjunctivitis (51/59 [86%]), keratitis (51 [86%]), blepharitis (19 [32%]), nasal discharge or sneezing (10 [17%]), and dermatitis (4 [7%]) were common findings. Clinical improvement was subjectively graded as marked in 30 (51%) cats, mild in 20 (34%), and nonapparent in 9 (15%). Median time to improvement was significantly shorter, and degree of improvement was significantly greater in the high-dose group than in the low-dose group. Adverse effects potentially attributable to famciclovir administration were reported for 10 cats. On the basis of survey responses, most (29/32 [91%]) owners were satisfied with their cat's treatment. CONCLUSIONS AND CLINICAL RELEVANCE Famciclovir at the prescribed dosages was associated with improved clinical signs in cats with presumed FHV-1 infection, and few adverse effects were attributed to the treatment. Further studies are needed to assess whether a famciclovir dosage of 90 versus 40 mg/kg, PO, 3 times/d would result in increased efficacy and shorter treatment time.
引用
收藏
页码:526 / 538
页数:13
相关论文
共 30 条
  • [1] Single-day, patient-initiated famciclovir therapy versus 3-day valacyclovir regimen for recurrent genital herpes: A randomized, double-blind, comparative trial
    Abudalu, Mohammed
    Tyring, Stephen
    Koltun, William
    Bodsworth, Neil
    Hamed, Kamal
    [J]. CLINICAL INFECTIOUS DISEASES, 2008, 47 (05) : 651 - 658
  • [2] Single-Dose Pharmacokinetics of Famciclovir in Infants and Population Pharmacokinetic Analysis in Infants and Children
    Blumer, Jeffrey
    Rodriguez, Adib
    Sanchez, Pablo J.
    Sallas, William
    Kaiser, Guenther
    Hamed, Kamal
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2010, 54 (05) : 2032 - 2041
  • [3] PHARMACOKINETICS OF FAMCICLOVIR IN SUBJECTS WITH VARYING DEGREES OF RENAL IMPAIRMENT
    BOIKE, SC
    PUE, MA
    FREED, MI
    AUDET, PR
    FAIRLESS, A
    ILSON, BE
    ZARIFFA, N
    JORKASKY, DK
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1994, 55 (04) : 418 - 426
  • [4] METABOLIC AND PHARMACOKINETIC STUDIES FOLLOWING ORAL-ADMINISTRATION OF FAMCICLOVIR TO THE RAT AND DOG
    FILER, CW
    RAMJI, JV
    ALLEN, GD
    BROWN, TA
    FOWLES, SE
    HOLLIS, FJ
    MORT, EE
    [J]. XENOBIOTICA, 1995, 25 (05) : 477 - 490
  • [5] A Comparative Study to Evaluate the Efficacy and Safety of Acyclovir and Famciclovir in the Management of Herpes Zoster
    Gopal, M. G.
    Sharmoma
    Kumar, Sharath B. C.
    Ramesh, M.
    Nandini, A. S.
    Manjunath, Namrata C.
    [J]. JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH, 2013, 7 (12) : 2904 - 2907
  • [6] FELINE HERPESVIRUS-1 Ocular manifestations, diagnosis and treatment options
    Gould, David
    [J]. JOURNAL OF FELINE MEDICINE AND SURGERY, 2011, 13 (05) : 333 - 346
  • [7] Groth AD, 2010, VET OPHTHALMOLOGY, V13, P416
  • [8] Famciclovir substitution for patients with acyclovir-associated renal toxicity
    Htwe, Tin Han
    Bergman, Scott
    Koirala, Janak
    [J]. JOURNAL OF INFECTION, 2008, 57 (03) : 266 - 268
  • [9] Development of a quantitative real-time TaqMan PCR assay for testing the susceptibility of feline herpesvirus-1 to antiviral compounds
    Hussein, Islam T. M.
    Field, Hugh J.
    [J]. JOURNAL OF VIROLOGICAL METHODS, 2008, 152 (1-2) : 85 - 90
  • [10] Penciclovir is a potent inhibitor of feline herpesvirus-1 with susceptibility determined at the level of virus-encoded thymidine kinase
    Hussein, Islam T. M.
    Menashy, Rebecca V.
    Field, Hugh J.
    [J]. ANTIVIRAL RESEARCH, 2008, 78 (03) : 268 - 274